FDA Requires Safety Labeling Changes for GLP-1 Receptor Agonists Due to Potential Increased Risk of Rare Eye Condition

The U.S. Food and Drug Administration (FDA) is requiring manufacturers of glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications to update their safety labels. This action is due to a potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAION), a rare but serious eye condition that can lead to sudden, painless vision loss, including permanent blindness. The new warning will be added to the Warnings and Precautions section of the drug labeling for all GLP-1 RA medications, a class widely used for type 2 diabetes and obesity, including popular treatments like Ozempic, Wegovy, Mounjaro, and Zepbound. The FDA's assessment included an analysis of 126 clinical trials and real-world data, which consistently reported an increased risk of NAION in patients initiating GLP-1 RAs compared to other diabetes medications.